MTOR and pachyonychia congenita: Therefore, our results implicate that NR2F1-AS1 contributes to PC development through NR2F1 and the AKT/mTOR pathway, which involved in a hypoxic microenvironment, providing a potential prognostic biomarker and therapeutic target for PC.